Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged
coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), …

Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-CoV-2
infection is crucial for understanding immune protection and identifying targets for …

Efficient therapeutic options are needed to control the spread of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 …

The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding
domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little …

The spillovers of betacoronaviruses in humans and the emergence of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants highlight the need for broad coronavirus …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …

The recent emergence of SARS-CoV-2 variants of concern 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 – 10
and the recurrent spillovers of coronaviruses 11 , 12 into the human population highlight the …

VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs) targeting the spike
glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-7831 …

Influenza virus remains a threat because of its ability to evade vaccine-induced immune
responses due to antigenic drift. Here, we describe the isolation, evolution, and structure of a …

Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots
in the receptor-binding domain 1 (RBD) of the spike protein. The effects of these mutations …